Please ensure Javascript is enabled for purposes of website accessibility

The 3 Biggest Takeaways From Intuitive Surgical's Impressive Quarter

By Brian Stoffel – Oct 19, 2019 at 12:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sure, procedures were up -- but these factors are just as important.

As has been the case for almost five years now, Intuitive Surgical (ISRG 4.48%) reported another impressive quarter Thursday night. The company's da Vinci robotic surgical system has truly become the standard-bearer for minimally invasive surgery. That has helped Intuitive earn a special place in the hearts of healthcare investors.

While there were, as always, lots of details to keep track of in the third-quarter results, three major themes continued to play out. Watching all three will help you keep track of your investment in the stock.

Surgeons in operating room with daVinci machinery

Image source: Intuitive Surgical.

1. Procedure growth is very strong

Five years ago, benign hysterectomies accounted for a huge swath of Intuitive's procedures. When the efficacy of those procedures was called into question, growth came to a standstill.

Since then, the company has flourished. As doctors continually tinker with how the machine can help improve surgical outcomes, the company has found more procedures where it can make a real difference. 

Chart showing procedure growth by quarter at Intuitive Surgical

Data source: SEC filings.

That growth has been two-pronged. There's U.S. general surgery, a catch-all category that has been spurred by tremendous growth in hernia and colorectal procedures. And in the conference call Thursday night, management also singled out cholecystectomy (gall bladder removal) as a "significant driver of incremental procedures."

The other source is international growth. As more countries start warming to the idea of robot-assisted surgery, growth has been impressive. For the third quarter, operations outside of the United States increased 23%, with particularly high growth of 40% in Japan.

2. Greasing the wheels for continued adoption

Much has been made recently of competition finally entering the industry. For a long time, Intuitive's main competition was simply from traditional laparoscopic procedures. But Medtronic changed that when it recently unveiled its own robotic surgical system.

It will be an uphill battle for Medtronic. At the end of the quarter, Intuitive's installed base of da Vinci machines stood at 5,406. Think about that: It represents tens of thousands of doctors who have spent millions of hours practicing and performing surgery with this platform. To switch to the competition, Medtronic would have to be offering something an order of magnitude better than da Vinci.

Even so, Intuitive is doing everything it can to get the machine into as many hospitals as possible. Over the past two years, that has meant creating operating lease agreements to sell its systems. 

Sometimes, hospitals balk at buying a da Vinci. The selling price is often over $1.5 million -- a serious investment for U.S. hospitals, and even more so in developing economies. To help grease the wheels for continued adoption (read: market share), Intuitive offers financing that lowers these obstacles.

During the third quarter, Intuitive sold 275 systems. A full third of those were placed using alternative financing -- something that wasn't even considered a few years back. This is a shrewd move by management: While it may lower short-term profits, it raises the possibility for long-term dominance by locking in hospitals (and the recurring revenue their procedures generate) for the long haul.

3. A cash machine

The strength of Intuitive's balance sheet cannot be overlooked. The company ended the quarter with $5.4 billion in cash on hand versus zero long-term debt. And that was even after share repurchases, the acquisition of a smaller business, and investments to build up inventory.

Right now, non-GAAP earnings are growing slower than revenue: 21% versus 23%. Investors never like seeing that, since it's a sign that a company doesn't have leverage.

But with Intuitive, context is necessary. The company is aggressively reinvesting in international opportunities, as well as a spate of new products that are being released. If history is any indication, these could pay off handsomely. The bigger point: Despite those investments, Intuitive is a cash machine that should have no problem reinvesting for its future.

That's why, as a shareholder myself, I couldn't be happier with this report.

Brian Stoffel owns shares of Intuitive Surgical. The Motley Fool owns shares of and recommends Intuitive Surgical. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intuitive Surgical Stock Quote
Intuitive Surgical
ISRG
$270.39 (4.48%) $11.59
Medtronic Plc Stock Quote
Medtronic Plc
MDT
$79.04 (3.35%) $2.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.